Research progress in individualized administration of mercaptopurine for children with acute ;lymphoblastic leukemia
10.3760/cma.j.issn.1008-5734.2016.02.009
- VernacularTitle:巯嘌呤治疗儿童急性淋巴细胞白血病个体化给药研究进展
- Author:
Kangkang MEI
1
;
Zhihong LUO
;
Jian WANG
;
Lijun QU
Author Information
1. 安徽省儿童医院药剂科, 合肥,230051
- Publication Type:Journal Article
- Keywords:
6-mercaptopurine;
LeuKemia,lYmphoid;
Individualized medicine
- From:
Adverse Drug Reactions Journal
2016;18(2):121-125
- CountryChina
- Language:Chinese
-
Abstract:
Mercaptopurine is used to treat children with acute lYmphoblastic leuKemia. Mercaptopurine can cause bone marrow suppression and liver toxicitY,threatening the lives of children, resulting in interruption or discontinuation of the chemotherapY,increasing the risK of disease recurrence. The mercaptopurine dosage regimens should be adjusted according to drug metabolizing enzYme genotYpes, detection of intra-erYthrocYtic metabolic products, and creating a phYsical model. Individualized administration should be adopted in order to improve the efficacY and safetY of mercaptopurine.
